Skip to main content
Fig. 7 | Diabetology & Metabolic Syndrome

Fig. 7

From: Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Fig. 7

Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel a), glucose-6-phosphatase (Panel b), and PEPCK (Panel c). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us